Research showing that the risk of diabetes and mortality increases after adults switch from antidepressants to second-generation antipsychotics will be the subject of a special CHEPA seminar presented by William P. Warburton, PhD, on Friday, June 22.
Since becoming available in the 1990s, second-generation antipsychotics (SGAs) have been prescribed with increasing frequency. Previously used primarily to treat psychosis, their main use is now for depression. Use of SGAs is associated with rapid weight gain, however, their long-term impact on diabetes and mortality in middle-aged adults is unknown. Warburton will discuss results of a study involving 40 to 60-year-olds in British Columbia who had been treated for depression with an antidepressant and switched to another antidepressant or to a SGA, which found that adults with depression treated with an SGA face both an increased risk of developing diabetes and an increased risk of mortality.
The seminar will take place in CRL B119, from 12:00 p.m. to 1:30 p.m. All are welcome to attend. The seminar will be available remotely for those who are unable to attend. Click here for instructions on how to listen to the presentation through Elluminate.